文献速递MDS 与骨髓增殖性肿瘤白血病

ETV6突变型髓系肿瘤的临床与分子谱

The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms.
PubMed 文献 · Br J Haematol · 2023-05-05

该研究在5793例接受髓系肿瘤检查的患者中检出33例(0.6%)携带致病性ETV6突变,多见于高危疾病类型。ETV6突变常为亚克隆性,且从不单独出现,常与ASXL1、SRSF2、SETBP1共突变。队列中位总生存期为17.5个月。

要点

  • ETV6突变见于0.6%(33/5793)的髓系肿瘤检查病例,主要在高危疾病中。
  • ETV6突变常为亚克隆性,并与ASXL1(75%)、SRSF2(42%)、SETBP1(33%)共突变。
  • 在MDS患者中,ETV6突变者ASXL1、SETBP1、RUNX1和U2AF1突变率高于野生型对照。

核心结论

  • 本报告强调了髓系肿瘤中体细胞ETV6突变的临床与分子关联,提示其作为晚期事件发生,并提出进一步转化研究问题。

研究设计与样本

  • 研究纳入5793例接受髓系肿瘤检查的患者,检出33例(0.6%)携带致病性ETV6突变。

主要发现

  • ETV6突变主要见于高危疾病实体,包括伴原始细胞增多的MDS、原发性骨髓纤维化和AML伴骨髓增生异常相关改变。
  • 3例同时检出孤立性iso(17q)核型,该核型在髓系肿瘤中罕见。
  • ETV6突变常为亚克隆性,且从不作为孤立异常出现;主要共突变为ASXL1(n=22,75%)、SRSF2(n=14,42%)和SETBP1(n=11,33%)。
  • 在MDS患者中,ETV6突变者ASXL1、SETBP1、RUNX1和U2AF1突变率高于ETV6野生型的连续对照队列。
  • 队列中位总生存期为17.5个月。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETV6 mutations are rare but recurrent somatic events in myeloid neoplasms and are negatively prognostic in myelodysplastic syndrome. We set out to examine the clinical and molecular characteristics of patients undergoing investigation for myeloid neoplasms, found to have deleterious ETV6 mutations. ETV6 mutations occurred in 33 of 5793 (0.6%) cases investigated and predominantly in high-risk disease entities including MDS with increased blasts, primary myelofibrosis and AML, myelodysplasia-related. In three cases, isolated iso (17q) karyotype was concurrently detected, an otherwise rare karyotype in myeloid neoplasms. ETV6 mutations were frequently subclonal and never occurred as an isolated abnormality with ASXL1 (n = 22, 75%), SRSF2 (n = 14, 42%) and SETBP1 (n = 11, 33%) the predominant co-mutations. Restricting to patients with MDS, higher rates of ASXL1, SETBP1, RUNX1 and U2AF1 mutations occurred in ETV6 mutated cases, relative to a consecutive control cohort with wild-type ETV6. The median OS of the cohort was 17.5 months. This report highlights the clinical and molecular associations of somatic ETV6 mutations in myeloid neoplasms, suggests their occurrence as a later event, and proposes further translational research questions for their role in myeloid neoplasia.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Gurney M, Chekkaf I, Baranwal A, et al. The clinical and molecular spectrum of ETV6 mutated myeloid neoplasms. Br J Haematol. 2023. PMID: 37144345. doi:10.1111/bjh.18850

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。